Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Catane

Showing results (61-70 of 112) with videos related to

Pageof 12
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1986
Adriamycin, vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancerA Sulkes, E Gez, M R Pfeffer, et al.
Cancer Treatment Reports|December 1, 1977
Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapyM S Didolkar, R R Baffi, R Catane, et al.
Cancer Research|November 1, 1980
Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazoleJ J Clement, M S Gorman, I Wodinsky, et al.
Harefuah|July 1, 1986
[Nuclear magnetic resonance in the diagnose of spinal malignancy]R Ben-Joseph, R Catane, A Libson, et al.
Cancer Treatment Reports|September 1, 1978
Phase I study of N6-benzyladenosine-5'-monophosphateR Catane, J H Kaufman, F A Nime, et al.
Cancer|December 1, 1976
Brain metastasis from prostatic carcinomaR Catane, J Kaufman, C West, et al.
International Journal of Cancer|March 30, 2000
Synergistic anti-tumoral effect of paclitaxel (Taxol)+AS101 in a murine model of B16 melanoma: association with ras-dependent signal-transduction pathwaysY Kalechman, D L Longo, R Catane, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1993
Estimation of creatinine clearance without 24-hour urine collection--a useful guide during cisplatin therapyN Haim, S D Oman, N Galai, et al.
Medical and Pediatric Oncology|January 1, 1985
Secondary myelofibrosis with metastatic breast cancer simulating agnogenic myeloid metaplasia: report of a case and review of the literatureT Yablonski-Peretz, A Sulkes, A Polliack, et al.
Gynecologic Oncology|December 31, 1997
High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family historyU Beller, D Halle, R Catane, et al.
Pageof 12

Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
Cancer Chemotherapy and Pharmacology|January 1, 1986
Adriamycin, vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancerA Sulkes, E Gez, M R Pfeffer, et al.
Cancer Treatment Reports|December 1, 1977
Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapyM S Didolkar, R R Baffi, R Catane, et al.
Cancer Research|November 1, 1980
Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazoleJ J Clement, M S Gorman, I Wodinsky, et al.
Harefuah|July 1, 1986
[Nuclear magnetic resonance in the diagnose of spinal malignancy]R Ben-Joseph, R Catane, A Libson, et al.
Cancer Treatment Reports|September 1, 1978
Phase I study of N6-benzyladenosine-5'-monophosphateR Catane, J H Kaufman, F A Nime, et al.
Cancer|December 1, 1976
Brain metastasis from prostatic carcinomaR Catane, J Kaufman, C West, et al.
International Journal of Cancer|March 30, 2000
Synergistic anti-tumoral effect of paclitaxel (Taxol)+AS101 in a murine model of B16 melanoma: association with ras-dependent signal-transduction pathwaysY Kalechman, D L Longo, R Catane, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1993
Estimation of creatinine clearance without 24-hour urine collection--a useful guide during cisplatin therapyN Haim, S D Oman, N Galai, et al.
Medical and Pediatric Oncology|January 1, 1985
Secondary myelofibrosis with metastatic breast cancer simulating agnogenic myeloid metaplasia: report of a case and review of the literatureT Yablonski-Peretz, A Sulkes, A Polliack, et al.
Gynecologic Oncology|December 31, 1997
High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family historyU Beller, D Halle, R Catane, et al.
Pageof 12